News

News

Jul 01, 2022

JIXING Announces the First Patient Enrollment in Phase 3 Study of Etripamil in China

Jun 29, 2022

JIXING Announces Receipt of Clinical Trial Application Approval for China Cohort of Phase 3 Clinical Trial of Aficamten

May 09, 2022

Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

Apr 20, 2022

JIXING Announces Leadership Transition

Apr 13, 2022

LENZ Therapeutics and JiXing Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

Mar 31, 2022

JiXing Announces The Appointment Of Kun Wu As The Chief Commercial Officer

Mar 21, 2022

JiXing Announces Receipt Of Clinical Trial Application Approval For OC-01 Nasal Spray Phase 3 Trial For The Treatment Of Signs And Symptoms Of Dry Eye Disease In China

Mar 17, 2022

JiXing Presents Results Of China Phase 1 Study Of Aficamten At The 2022 American Society For Clinical Pharmacology And Therapeutics Annual Meeting

Feb 16, 2022

JiXing Announces Receipt Of Breakthrough Therapy Designation For Aficamten In China

Feb 04, 2022

Cytokinetics Announces FDA Acceptance Of New Drug Application For Omecamtiv Mecarbil For The Treatment Of Heart Failure With Reduced Ejection Fraction

Dec 20, 2021

Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics

Dec 3, 2021

Ji Xing completes Phase 1 study of aficamten, a potential next-generation cardiac myosin inhibitor, for patients with hypertrophic cardiomyopathy (HCM)

Nov 19, 2021

JIXING Announces IND Approval for Phase 1 and Phase 3 Clinical Trials of Etripamil in Patients with Paroxysmal Supraventricular Tachycardia (PSVT) in China

Aug 6, 2021

Chinese startup with Merck vet at the helm acquires rights to Oyster Point’s eye disease nasal spray

Aug 5, 2021

Oyster Point Pharma Announces Exclusive License Agreement with JIXING Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China

Jul 13, 2021

RTW Investments-Backed JIXING Pharmaceuticals Appoints Joseph Romanelli Chief Executive Officer

May 17, 2021

Milestone Pharmaceuticals Announces Exclusive License Agreement with JIXING Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China

Jul 14, 2020

RTW Investments, LP, JIXING Pharmaceuticals and Cytokinetics Enter Intro Strategic Financing Collaboration to Support the Development of CK-274 and Enter China

View All News